A primary catalyst for the sector stems from evolving regulations. The FDA Modernization Act 2.0 is creating a favorable environment by encouraging the use of advanced digital models over traditional ...
The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...
VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (ABSI) (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to ...
Advanced Micro Devices Inc. today announced that it has invested $20 million in Absci Corp., a company using artificial intelligence to develop new medicines. AMD will also partner with the company to ...
HC Wainwright reiterated their buy rating on shares of Absci (NASDAQ:ABSI – Free Report) in a research report report published on Wednesday,Benzinga reports. They currently have a $7.00 price target ...
Absci (NASDAQ:ABSI – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Guggenheim in a research note issued to investors on Thursday,Benzinga reports. They presently have ...
Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results